Research programme: follicle-stimulating hormone agonists oral - TocopheRx

Drug Profile

Research programme: follicle-stimulating hormone agonists oral - TocopheRx

Alternative Names: FSH agonist - TocopheRx

Latest Information Update: 28 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EMD Serono
  • Developer TocopheRx
  • Class
  • Mechanism of Action Follicle stimulating hormone stimulants; Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Female infertility; Male infertility

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Female-infertility in USA (PO)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Male-infertility in USA (PO)
  • 02 Dec 2013 EMD Serono forms spin-off company TocopheRx for further development of its infertility programme in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top